A 35-year-old man with a history of tuberculosis on anti-TB therapy (rifampicin, isoniazid, pyrazinamide, ethambutol) presents with fever, widespread erythematous macules progressing to blisters and erosions involving 45% of body surface area, including the face, trunk, and extremities. Mucosal involvement is extensive (oral, ocular, and genital). Laboratory findings show leukocytosis (WBC 14,000/μL), elevated transaminases (AST 120 U/L, ALT 140 U/L), and mild thrombocytopenia (platelets 110,000/μL). What is the most appropriate immediate next step in management?

Explanation

## Management of Toxic Epidermal Necrolysis (TEN) in a TB Patient ### Clinical Diagnosis: TEN **Key Point:** This patient has **45% BSA** involvement with extensive mucosal erosions (oral, ocular, genital) — this is **Toxic Epidermal Necrolysis (TEN)**, the most severe end of the SJS-TEN spectrum. TEN carries a mortality of 25–35% and is a dermatological emergency. **High-Yield:** Anti-TB drugs — particularly **rifampicin, isoniazid, and pyrazinamide** — are among the most common causative agents of SJS/TEN worldwide, especially in high-TB-burden settings (Harrison 21e, Ch 56; Fitzpatrick's Dermatology 9e). --- ### Most Appropriate Immediate Next Step: Discontinue All Anti-TB Drugs + Switch Regimen; Avoid Corticosteroids **The single most critical intervention in drug-induced TEN is immediate withdrawal of the offending drug(s).** When the causative agent is a member of a multi-drug regimen (as here), all drugs in the regimen should be stopped until the culprit is identified, because continued exposure perpetuates epidermal necrosis and worsens prognosis. Delay in drug withdrawal is the strongest predictor of mortality in TEN (SCORTEN-validated data). **Why NOT corticosteroids in this TB patient?** | Consideration | Detail | |---|---| | **Corticosteroids in TEN** | Controversial; current evidence (EuroSCAR, RegiSCAR) does NOT support routine systemic corticosteroids as first-line in TEN — they may increase infection risk and delay re-epithelialization | | **TB-specific risk** | Corticosteroids cause significant immunosuppression; in active TB, they risk dissemination, miliary TB, and TB meningitis unless the patient is on fully effective anti-TB therapy | | **Current guidelines** | IVIG and cyclosporine (not corticosteroids) are the preferred adjunctive agents in TEN per most current guidelines (Mockenhaupt 2011; Creamer et al. BJD 2016) | **Alternative TB regimen:** After stopping all four drugs, a TB specialist should design an alternative regimen using agents with lower SJS/TEN risk (e.g., fluoroquinolones such as levofloxacin, aminoglycosides, cycloserine) to prevent TB treatment failure. --- ### Why Other Options Are Wrong **Option A (Continue anti-TB + corticosteroids):** Continuing the offending drugs is the most dangerous error in TEN management — it perpetuates the immune-mediated epidermal destruction. Additionally, systemic corticosteroids are NOT recommended as first-line in TEN (risk of infection, delayed healing) and are particularly hazardous in active TB. **Option C (Biopsy + empirical antibiotics/antifungals):** Skin biopsy, while confirmatory, is not the *immediate* next step — clinical diagnosis of TEN is sufficient to act. Prophylactic broad-spectrum antibiotics are not indicated and increase antimicrobial resistance; they are reserved for documented infection. **Option D (Plasmapheresis + IVIG as first-line):** IVIG has been used adjunctively in TEN, but evidence for benefit is mixed (Bachot et al. 2003 showed no mortality benefit). Plasmapheresis is experimental. Neither is considered first-line therapy; supportive care and drug withdrawal remain the cornerstones. --- ### Immediate Management Summary 1. **Stop all anti-TB drugs immediately** (rifampicin, isoniazid, pyrazinamide, ethambutol) 2. **Admit to ICU or burns unit** for supportive care (fluid resuscitation, wound care, nutritional support) 3. **Consult TB specialist** to design an alternative anti-TB regimen 4. **Ophthalmology, ENT, urology** consultations for mucosal involvement 5. **Do NOT initiate systemic corticosteroids** in this active TB patient 6. Consider **cyclosporine** (3–5 mg/kg/day) as adjunctive therapy if no contraindication **Clinical Pearl:** The SCORTEN score should be calculated on admission to predict mortality and guide ICU resource allocation. Each point increase in SCORTEN raises mortality by ~12%. [cite: Harrison 21e Ch 56; Fitzpatrick's Dermatology 9e Ch 41; Creamer D et al. BJD 2016; Mockenhaupt M. Curr Allergy Asthma Rep 2014]